Percheron Therapeutics Toekomstige groei

Future criteriumcontroles 5/6

Percheron Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 19.8% en 45.3% per jaar. De winst per aandeel zal naar verwachting groeien met 29% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -231.6% zijn.

Belangrijke informatie

19.8%

Groei van de winst

29.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.9%
Inkomstengroei	45.3%
Toekomstig rendement op eigen vermogen	-231.6%
Dekking van analisten	Low
Laatst bijgewerkt	07 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

OTCPK:PERC.F - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	11	6	-38	-38	2
6/30/2026	1	-20	-16	-16	3
6/30/2025	1	-40	-17	-17	2
6/30/2024	3	-12	-10	-10	N/A
3/31/2024	3	-11	-10	-10	N/A
12/31/2023	2	-11	-10	-10	N/A
9/30/2023	2	-11	-9	-9	N/A
6/30/2023	2	-11	-8	-8	N/A
3/31/2023	2	-10	-7	-7	N/A
12/31/2022	2	-8	-7	-7	N/A
9/30/2022	2	-7	-7	-7	N/A
6/30/2022	2	-6	-8	-8	N/A
3/31/2022	1	-7	-8	-8	N/A
12/31/2021	1	-9	-8	-8	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-8	-6	-6	N/A
3/31/2021	1	-6	-5	-5	N/A
12/31/2020	1	-4	-4	-4	N/A
9/30/2020	1	-5	-4	-4	N/A
6/30/2020	1	-6	-4	-4	N/A
3/31/2020	1	-6	-3	-3	N/A
12/31/2019	1	-6	-3	-3	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	0	-3	-3	-3	N/A
12/31/2018	0	-3	-3	-3	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	N/A	-2	N/A
12/31/2017	0	-2	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	2	-2	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	4	1	N/A	0	N/A
9/30/2015	5	1	N/A	1	N/A
6/30/2015	5	1	N/A	1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	1	-3	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat PERC.F de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat PERC.F de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat PERC.F binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van PERC.F ( 45.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van PERC.F ( 45.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat PERC.F binnen 3 jaar verliesgevend zal zijn.

Percheron Therapeutics Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven